Last reviewed · How we verify
viscosupplementation 1+1+1
Viscosupplementation 1+1+1 is a hyaluronic acid-based intra-articular injection that restores joint lubrication and provides cushioning to damaged cartilage.
Viscosupplementation 1+1+1 is a hyaluronic acid-based intra-articular injection that restores joint lubrication and provides cushioning to damaged cartilage. Used for Osteoarthritis of the knee, Joint pain and dysfunction secondary to osteoarthritis.
At a glance
| Generic name | viscosupplementation 1+1+1 |
|---|---|
| Also known as | 1+1+1 |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Hyaluronic acid derivative; viscosupplement |
| Target | Hyaluronic acid receptor (CD44); joint synovial fluid |
| Modality | Small molecule |
| Therapeutic area | Orthopedics; Rheumatology |
| Phase | FDA-approved |
Mechanism of action
This formulation combines hyaluronic acid components in a 1+1+1 ratio to create a viscoelastic fluid that mimics natural synovial fluid. It reduces friction between joint surfaces, absorbs shock, and may provide anti-inflammatory effects to alleviate pain and improve joint mobility in osteoarthritis.
Approved indications
- Osteoarthritis of the knee
- Joint pain and dysfunction secondary to osteoarthritis
Common side effects
- Injection site pain or swelling
- Transient joint effusion
- Local inflammation
Key clinical trials
- Safety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2) (NA)
- Clinical Investigation of Sensovisc (NA)
- Safety and Efficacy of Viscosupplementation of Hyaluronic Acid With Addition of Lecithin in Patients With Mild or Moderate Osteoarthrosis of the Knee Joint. (NA)
- Trial Comparing Three Single Dose Injections for Knee Osteoarthritis (PHASE4)
- Synvisc-One for Younger, Active Patients With Osteoarthritis (NA)
- Stem Cell and Growth Factor Injury and Arthritis Clinical Research Study (NA)
- Efficacy and Safety of a Intra-articular Injection, ENKO1, in Patients With Symptomatic Knee Osteoarthritis. (NA)
- Study of Viscosupplementation for the Treatment of Knee Pain After Menisectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- viscosupplementation 1+1+1 CI brief — competitive landscape report
- viscosupplementation 1+1+1 updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI